Relationship between the expression of LAT1,CD98hc and clinical pathological characteristics of gastric carcinoma

Abstract

Abstract: AIM: To investigate the expression of L-type amino acid transporter-1(LAT1), CD98hc in gastric carcinoma and elucidate the relationship between their overexpression and clinical pathological characteristics.METHODS: The expression of LAT1, CD98hc and Ki67 in 45 cases of gastric cancer, 45 cases of adjacent normal gastric tissue were detected by using semiquantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry.RESULTS: RT-PCR analysis showed that the expression of LAT1, CD98hc mRNA in gastric carcinoma tissues were significantly higher than those in adjacent normal gastric tissues(P<0.05). Immunohistochemistry showed that the positive rate of LAT1 accounted for 64.4% (29/45) in gastric carcinoma, and 6.67% in adjacent normal gastric tissues (P<0.01). The positive expression rate of CD98hc was 60.0% in gastric carcinoma tissues, and 22.2% in adjacent normal gastric tissues (P<0.01). The expression of LAT1, CD98hc in poorly differentiated gastric carcinoma, stage Ⅲ-Ⅳ were significantly higher those in well differentiated gastric carcinoma, stage Ⅰ-Ⅱ(P<0.05). In gastric cancer with lymph metastasis, tumor size ≥5 cm, their expression were significantly higher than that in gastric cancer without lymph metastasis, tumor size ＜5 cm(P<0.05). The higher expression of LAT1, CD98hc were positive correlated to Ki67 in gastric carcinoma (P<0.01).CONCLUSION: LAT1, CD98hc specifically highly express in gastric carcinoma. The abnormal expression may play an important role in the carcinogenesis and metastasis of gastric carcinoma.

Key words: LAT1, CD98hc, Gastric carcinoma, RT-PCR, Immunohistochemistry

CLC Number:

R573

SHI Liang-hui, ZHANG Cai-quan, PENG Xiao-zhuang. Relationship between the expression of LAT1,CD98hc and clinical pathological characteristics of gastric carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(12): 1361-1366.

References

[1] Yanagida O, Kanai Y, Chairoungdua A,et al.Human L-type amino acid trans- porter 1(LAT1):characterization of function and expression in tumor cel1 lines[J].Biochim Biophys Acta,2001,1514(2):291-302.
[2] Asano S,Kameyama M,Oura A,et al.L-type amino acid transporter-1 expressed in human astrocytomas,U343MGa[J].Biol Pharm Bull,2007,30(3):415-422.
[3] Broer A,Wagner CA,Lang F,et al.The heterodimeric amino acid trans- porter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glu- tamine[J].Biochem J,2000,349(Pt3):787-795.
[4] Broer S,Wagner CA.Structure-function relationships of heterodimeric amino acid transporters[J].Cell Biochem Biophys,2002,36(2/3):155-168.
[5] Jain-Vakkalagadda B, Dey S, Pal D, et al. Identification and functional characteriza -tion of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea[J]. Invest Ophthalmol Vis Sci, 2003,44 (7):2919-2927.
[6] Kanai Y, Segawa H, Mivamoto K, et al.Expression cloning and character- rization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen(CD98)[J].J Biol Chem,1998,273(37):23629-23632.
[7] Bodoy S, Martin L, Zorzano A, et al.Identification of LAT4,a novel amino acid transporter with system L activity[J].J Biol Chem,2005,280(12): 12002-12011.
[8] Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer:partners in crime[J] ? Seminars Cancer Biol, 2005, 15(4): 254-266.
[9] Ohkame H, Masuda H, Ishii Y, et al. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models[J]. J Surg Oncol,2001,78(4): 265-271.
[10] Tamai S, Masuda H, Ishii Y, et al. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size[J]. Cancer Detect Prev, 2001,25(5): 439-445.
[11] Nakanishi K, Matsuo H, Kanai Y, et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung[J]. Virchows Arch, 2006,448(2):142-150.
[12] Ohkame H, Masuda H, Ishii Y, et al. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models[J]. J Surg Oncol, 2001,78(4):265-271.
[13] Lin J, Raoof DA,Thomas DG,et a1.L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma[J]. Neoplasia,2004,6(1):74-84.
[14] Baniasadi S, Chairoungdua A, Iribe Y, et a1.Gene expression profiles in T24 human bladder carcinoma cells by inhibiting an L-type amino acid transporter,LAT1[J].Arch Pharm Res,2007,30(4): 444-452.

[1]	FANG Chuanchuan, NI Guantai, JIN Lan, LIU Ji, LIU Xiaoqing, QIAO Chun, LUO Yonghong. Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 523-528.
[2]	PENG Jun-lu, SHI Liang-hui, LI Fan-hong, ZHAO Dun-dun. Significance of ubiquitin ligase hrd1 expressed in human gastric carcinoma and normal cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 314-317.
[3]	ZHANG Xue-fei, ZHU Xuan-xuan, LIU Shen-lin, WANG Qiong, YAN Shi-hai, WANG Hai-dan, ZHANG Di, FU Rui. Effect of Weiliuan of different prescriptions on proliferation and cell cycle of human gastric carcinoma cell line SGC-7901 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 31-37.
[4]	LUO Hui-ying, YANG Lin, WANG Xiao-peng, SU He, LIU Ying, MA Yun-tao, WU Zi-yan. Effects of siRNA silencing COX-2 gene on VEGF-C expression and cell migration in SGC-7901 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 961-966.
[5]	YUAN Dai-xiu, SHU Li-xia, HUANG Rong. Antitumor effects of total flavonoids of Eucommia ulmoides in tumor-bearing mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1332-1336.
[6]	CHENG Yuan-guang, WU Pei. Expression of somatostatin receptor type 2 in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1100-1104.
[7]	SHENG Li-li, LIU Yin-hua, JI Zhao-ning. Expression and significance of PTEN and LIVIN in diffuse large B-cell lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 376-380.
[8]	CHEN Hua, YING Wei-xing, LI Rong-zhou. Combined treatment of vitamin K₂ and benazepril induces apoptosis and inhibits angiogenesis on gastric cancer in vitro experiments [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 621-626.
[9]	HUANG Lai-quan, WEI Zhong-lin, ZHANG Jun, ZHANG Dai-yun, WANG Xing-hong. Expressions of BAG-1 and NF-κB P65 in the mononuclearcell of multiplemyeloma patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 292-297.
[10]	LI Hao-xia, CHEN Xiao-liang, MA Zhi-min. Study on cisplatin pharmacokinetics:preoperative intraperitoneal administration versus intravenous chemotherapy with cisplatin for advanced gastric carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 541-545.
[11]	LIU Hong-lin, CHEN Dai-xiong, FANG Ning, YU Li-mei, LIU Jin-wei, LIU Zu-lin, WEN Guo-rong, YANG Xiao-sheng, XIAO Yu, QI Ying, XIAO Jian-hui, WAN Wei-hong, HU Xi-jie. Effects of Rosa roxburghii Tratt extract-CL1 on gastric carcinoma SGC-7901 cells growth and human umbilical cord CD34+cells proliferation and differentiation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(7): 829-832.
[12]	LI Yun-man, KANG Kai, FANG Wei-rong. Lomerizine inhibits activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1110-1114.
[13]	YU Hong-e, YU Qing-sheng, LIU Xin-yan, ZHU Liu, LOU Xiao-hua, TENG Mai-kun. China cobra venom active factor (CCVAF) inhibits VEGF and bFGF in lung cancer cell line H1299 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 970-973.
[14]	WU Jia-bin, XU Chun-xuan, ZHANG Jian-cheng, CHEN Lin, LIN Li-fang, HU Xi-zhong. Study of chloride channel ClC-3 gene expression in patient with atrial fibrillation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(6): 651-654.
[15]	LU Zhi-hong, XIONG Xiao-yun, MENG Jing-ru, LIU Zhen-guo, WANG Zhi-peng, MEI Qi-bing. Changes of three COX isoforms expression after formalin induced inflammatory pain in brain and analgesic effects of different COX inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(5): 499-504.